University of Utah: Melanoma trials

The registry lists 17 Melanoma studies with University of Utah as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 5Phase 2 9No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rural Adult and Youth Sun Protection StudyRecruitingNCT06439979Not applicable
• Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingNCT06194929Phase 1/2
• Sun Protection and Tanning Awareness in Rural SchoolsCompletedNCT06694571Not applicableResults posted
• Family Lifestyles, Actions, and Risk Education Intervention: Version 2CompletedNCT04201223Not applicableResults posted
• Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaTerminatedNCT03259425Phase 2Results posted
• Family Lifestyle Actions and Risk Education StudyCompletedNCT02846714Not applicableResults posted
• Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line TherapyCompletedNCT02101008Phase 2Results posted
• Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in VivoCompletedNCT01612221Phase 2Results posted
• Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant MelanomaCompletedNCT00847522Phase 1/2Results posted
• Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant MelanomaTerminatedNCT00707161Phase 2Results posted
• Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaWithdrawnNCT06365619Phase 2
• Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)Active, not recruitingNCT05736523
• Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for MelanomaCompletedNCT04066725Phase 2
• Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for MelanomaCompletedNCT04062032Phase 2
• Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1
• Radiation Use During Vemurafenib TreatmentWithdrawnNCT01843738Phase 1
• A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV MelanomaCompletedNCT01672450Phase 1